Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
34 - Botulinum Toxin Therapy for Cranial Dystonia
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 167 - 171Publisher: Cambridge University PressPrint publication year: 2018
References
Albanese, A, Asmus, F, Bhatia, KP, Elia, AE, Elibol, B, Filippini, G, Gasser, T, Krauss, JK, Nardocci, N, Newton, A, Valls-Solé, J (2011). EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18.Google Scholar
Aramideh, M, Bour, LJ, Koelman, JH, Speelman, JD, Ongerboer de Visser, BW (1994). Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition: clinical and pathophysiological considerations. Brain 117:1457–1474.CrossRefGoogle ScholarPubMed
Brin, M, Danisio, F, Blitzer, A (2003). Blephaospasm, oromandibular dystonia, Meige’s syndrome and hemifacial spasm. In: Moore, AP, Naumann, M (eds) Handbook of Botulinum Toxin Treatment. Oxford: Blackwell Scientific.Google Scholar
Colosimo, C, Chianese, M, Contarino, F, Giovannelli, M, Bentivoglio, AR (2003). Botulinum toxin type B in blepharospasm and hemifacial spasm. J Neurol, Neurosurg Psychiatry 74:687.CrossRefGoogle ScholarPubMed
Colosimo, C, Suppa, A, Fabbrini, G, Bologna, M, Berardelli, A (2010). Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17 (Suppl. 1):15–21.Google Scholar
Colosimo, C, Tiple, D, Berardelli, A (2012). Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22:265–273.Google Scholar
Defazio, G, Matarin, M, Peckham, EL, Peckham, EL, Martino, D, Valente, EM, Singleton, A, Crawley, A, Aniello, MS, Brancati, F, Abbruzzese, G, Girlanda, P, Livrea, P, Hallett, M, Berardelli, A (2009). The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm. Mov Disord 24(4):613–616.CrossRefGoogle ScholarPubMed
Girlanda, P, Quartarone, A, Sinicropi, S, Nicolosi, C, Messina, C (1996). Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord 11:27–31.Google Scholar
Gonzalez-Alegre, P, Schneider, RL, Hoffman, H (2014). Clinical, etiological, and therapeutic features of jaw-opening and jaw-closing oromandibular dystonias: a decade of experience at a single treatment center. Tremor Other Hyperkinet Mov (NY) 30(4):231.CrossRefGoogle Scholar
Grandas, F, Elston, J, Quinn, N, Marsden, CD (1988). Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 51:767–772.Google Scholar
Hallett, M, Albanese, A, Dressler, D, Segal, KR, Simpson, DM, Truong, D, Jankovic, J (2013). Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114.CrossRefGoogle ScholarPubMed
Hellman, A, Torres-Russotto, D (2015). Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord 8(2):82–91.Google Scholar
Jankovic, J, Ford, J (1983). Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411.CrossRefGoogle ScholarPubMed
Jankovic, J, Orman, J (1987). Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616–623.Google Scholar
Jankovic, J, Comella, C, Hanschmann, A, Grafe, S (2011). Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm: a randomized trial. Mov Disord 26:1521–1528.CrossRefGoogle ScholarPubMed
Kraft, SP, Lang, AE (1988). Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ 139:837–844.Google ScholarPubMed
Lee, SJ, McCall, WD Jr, Kim, YK (2010). Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil 89:16–23.CrossRefGoogle ScholarPubMed
Meige, H (1910). Les convulsions de la face: une forme clinique de convulsions faciales, bilaterales et mediane. Rev Neurol (Paris) 21:437–443.Google Scholar
Mendes, RA, Upton, LG (2009). Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg 47:481–483.Google Scholar
Nuessgens, Z, Roggenkamper, P (1997). Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmo 235:197–199.Google Scholar
Ramirez-Castaneda, J, Jankovic, J (2013). Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins 5:249–266.CrossRefGoogle ScholarPubMed
Roggenkamper, P, Jost, WH, Bihari, K, Comes, G, Grafe, S; NT 201 Blepharospasm Study Team (2006). Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312.Google Scholar
Schneider, SA, Aggarwal, A, Bhatt, M, Dupont, E, Tisch, S, Limousin, P, Lee, P, Quinn, N, Bhatia, KP (2006). Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 26(67):940–943.Google Scholar
Scott, AB, Rosenbaum, A, Collins, CC (1973). Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12:924–927.Google ScholarPubMed
Tan, EK, Jankovic, J (1999). Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53:2102–2107.CrossRefGoogle ScholarPubMed
Thompson, PD, Obeso, JA, Delgado, G, Gallego, J, Marsden, CD (1986). Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry 49:651–656.CrossRefGoogle ScholarPubMed
Truong, D, Comella, C, Fernandez, HH, Ondo, WG; Dysport Benign Essential Blepharospasm Study Group (2008). Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 14:407–414.Google Scholar
Wabbels, B, Reichel, G, Fulford-Smith, A, Wright, N, Roggenkämper, P (2011). Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 11:233–239.CrossRefGoogle Scholar
Weiss, EM, Hershey, T, Karimi, M, Racette, B, Tabbal, SD, Mink, JW, Paniello, RC, Perlmutter, JS (2006). Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181.Google Scholar